Medpace Holdings, Inc. $MEDP Shares Sold by Willis Investment Counsel

Willis Investment Counsel decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 23.2% in the fourth quarter, Holdings Channel reports. The fund owned 9,590 shares of the company’s stock after selling 2,894 shares during the period. Willis Investment Counsel’s holdings in Medpace were worth $5,386,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MEDP. AQR Capital Management LLC raised its holdings in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after acquiring an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares during the last quarter. Bares Capital Management Inc. raised its holdings in Medpace by 319.2% in the 2nd quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock valued at $49,302,000 after acquiring an additional 119,608 shares during the last quarter. Wasatch Advisors LP raised its holdings in Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after acquiring an additional 85,517 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $520.65 on Thursday. The stock has a market capitalization of $14.87 billion, a P/E ratio of 34.03, a PEG ratio of 2.39 and a beta of 1.39. The company has a 50 day moving average price of $476.51 and a 200 day moving average price of $537.42. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm’s quarterly revenue was up 32.0% on a year-over-year basis. During the same quarter last year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on MEDP shares. Truist Financial cut their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday, February 11th. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price objective for the company in a report on Tuesday, February 10th. Weiss Ratings downgraded shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. Finally, Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $486.67.

Insider Buying and Selling at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.